HAVN Life Sciences Inc.
HAVLF · OTC
1/31/2023 | 10/31/2022 | 7/31/2022 | 4/30/2022 | |
|---|---|---|---|---|
| Market Cap | $1 | $1 | $0 | $9 |
| - Cash | $0 | $0 | $0 | $1 |
| + Debt | $0 | $0 | $1 | $0 |
| Enterprise Value | $1 | $1 | $1 | $9 |
| Revenue | -$0 | $0 | $0 | $0 |
| % Growth | -103.8% | 363.5% | -68.6% | – |
| Gross Profit | -$0 | $0 | $0 | $0 |
| % Margin | 690.9% | 64.1% | 32.4% | 31.5% |
| EBITDA | -$1 | -$1 | -$1 | -$11 |
| % Margin | 5,733.3% | -191.7% | -1,334.3% | -5,169.6% |
| Net Income | -$1 | -$2 | -$4 | -$11 |
| % Margin | 5,734.1% | -787.5% | -5,747.4% | -5,253.1% |
| EPS Diluted | -0.071 | -0.41 | -27.05 | -2.38 |
| % Growth | 82.6% | 98.5% | -1,036.6% | – |
| Operating Cash Flow | $0 | -$1 | -$1 | -$1 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | $0 | -$1 | -$1 | -$1 |